Caribou Biosciences, Inc. Increase (Decrease) in Contract with Customer, Liability
Caribou Biosciences, Inc. (CRBU) reported Increase (Decrease) in Contract with Customer, Liability of -$1.85 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-13
- Caribou Biosciences, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was -$850.00K.
- Caribou Biosciences, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$1.00M.
- Caribou Biosciences, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$326.00K.
- Caribou Biosciences, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$627.00K.
- Caribou Biosciences, Inc. increase (decrease) in contract with customer, liability for fiscal 2025 was -$2.80M.
- Caribou Biosciences, Inc. increase (decrease) in contract with customer, liability for fiscal 2024 was -$2.50M.
- Caribou Biosciences, Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was -$16.94M.
- Caribou Biosciences, Inc. increase (decrease) in contract with customer, liability for fiscal 2022 was -$4.84M, a 116.34% decline from fiscal 2021.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$850.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$1.85M 10-Q · filed 2026-08-13 | -$2.18M derived: sum of 3 quarters · filed 2026-08-13 | -$2.81M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$1.00M 10-Q · filed 2026-05-07 | -$1.33M derived: sum of 2 quarters · filed 2026-05-07 | -$1.96M derived: sum of 3 quarters · filed 2026-05-07 | -$2.81M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$326.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$953.00K derived: sum of 2 quarters · filed 2026-03-05 | -$1.80M derived: sum of 3 quarters · filed 2026-08-13 | -$2.80M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$627.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.48M derived: sum of 2 quarters · filed 2026-08-13 | -$2.47M 10-Q · filed 2025-11-12 | -$2.80M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$849.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$1.84M 10-Q · filed 2026-08-13 | -$2.17M derived: sum of 3 quarters · filed 2026-08-13 | -$2.83M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$996.00K 10-Q · filed 2026-05-07 | -$1.33M derived: sum of 2 quarters · filed 2026-05-07 | -$1.98M derived: sum of 3 quarters · filed 2026-05-07 | -$2.81M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$330.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$988.00K derived: sum of 2 quarters · filed 2026-03-05 | -$1.81M derived: sum of 3 quarters · filed 2026-03-05 | -$2.50M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$658.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.48M derived: sum of 2 quarters · filed 2025-11-12 | -$2.17M 10-Q · filed 2025-11-12 | -$2.78M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$821.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$1.51M 10-Q · filed 2025-08-12 | -$2.12M derived: sum of 3 quarters · filed 2025-08-12 | -$23.69M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$694.00K 10-Q · filed 2025-05-08 | -$1.30M derived: sum of 2 quarters · filed 2025-05-08 | -$22.87M derived: sum of 3 quarters · filed 2025-05-08 | -$16.54M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$606.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$22.17M derived: sum of 2 quarters · filed 2025-03-10 | -$15.85M derived: sum of 3 quarters · filed 2025-03-10 | -$16.94M 10-K · filed 2025-03-10 |
| 2023-09-30 | -$21.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$15.24M derived: sum of 2 quarters · filed 2024-11-06 | -$16.34M 10-Q · filed 2024-11-06 | -$17.90M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $6.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $5.23M 10-Q · filed 2024-08-06 | $3.66M derived: sum of 3 quarters · filed 2024-08-06 | $2.86M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$1.10M 10-Q · filed 2024-05-07 | -$2.66M derived: sum of 2 quarters · filed 2024-05-07 | -$3.47M derived: sum of 3 quarters · filed 2024-05-07 | -$5.37M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$1.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | -$2.37M derived: sum of 2 quarters · filed 2024-03-11 | -$4.27M derived: sum of 3 quarters · filed 2024-03-11 | -$4.84M 10-K · filed 2024-03-11 |
| 2022-09-30 | -$807.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$2.71M derived: sum of 2 quarters · filed 2023-11-07 | -$3.28M 10-Q · filed 2023-11-07 | -$4.31M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$1.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$2.47M 10-Q · filed 2023-08-08 | -$3.50M derived: sum of 3 quarters · filed 2023-08-08 | |
| 2022-03-31 | -$572.00K 10-Q · filed 2023-05-09 | -$1.60M derived: sum of 2 quarters · filed 2023-05-09 | ||
| 2021-12-31 | -$1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $29.64M 10-K · filed 2023-03-09 | ||
| 2021-09-30 | $30.67M 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |